| Literature DB >> 16466913 |
M Trumper1, P J Ross, D Cunningham, A R Norman, R Hawkins, M Seymour, P Harper, T Iveson, M Nicolson, T Hickish.
Abstract
The aim of this study was to determine the benefits of chemotherapy for oesophago-gastric cancer (OGC) in patients 70 years and above (> or =70) in comparison to younger patients. 1080 patients were enrolled into three randomised controlled trials assessing fluorouracil-based combination chemotherapy. Patients received either a platinum-containing regimen (ECF, MCF), PVI 5-FU (protracted venous infusion of 5-fluorouracil)+/-mitomycin C (MMC), or FAMTX. Of the 1080 patients randomised, 257 (23.8%) were aged > or =70 years. There were no significant differences in the incidence of grades 3/4 toxicity between the two cohorts. Objective and symptomatic response rates, failure-free and overall survival were not significantly different. In a multivariate analysis, independent prognostic factors for survival were performance status and locally advanced disease, not age. Patients > or =70 years with OGC obtained similar benefits from palliative chemotherapy with respect to symptomatic response, tumour regression and survival, without increased toxicities.Entities:
Mesh：
Year: 2006 PMID： 16466913 DOI： 10.1016/j.ejca.2005.08.044
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162